PhD Postition

ERC-funded PhD position - Cardiovascular Immunology

A PhD position in the Tsiantoulas lab at the Medical University of Vienna is available.

We are looking for a highly motivated person to join our lab to study the function of the immune system in cardiovascular diseases and identify novel immunotherapies intended for clinical translation. For our studies, we utilize transgenic mice and a wide range of molecular biology techniques. This offers the great opportunity to learn and apply different experimental approaches to dissect the molecular machinery that drives inflammation in cardiovascular diseases. You will have the opportunity to collaborate with world experts in the field of cardiovascular immunology and present your work in high-profile international conferences.

The successful applicant should have a Master’s degree in immunology or molecular biology or related field. The candidate should be proactive and self-organized. Excellent oral as well as written communication skills are needed.

We offer

• an ERC-funded position

• an enthusiastic international working environment

• outstanding scientific resources

• the opportunity to collaborate with world-leaders in the field of cardiovascular immunology

Medical University of Vienna

The Medical University of Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training centre in the German-speaking countries. With 5,500 employees, 30 departments and two clinical institutes, 12 medical theory centres and numerous highly specialised laboratories, it is also one of Europe's leading research establishments in the biomedical sector www.meduniwien.ac.at/web/ .

Applicants should submit:

A motivation letter including a description of research interests, a detailed curriculum vitae, names and contact details of two referees. Please send all documents in English to: birgit.schlag-edler(at)meduniwien.ac.at

Applications will be reviewed on a rolling basis until December 20th, 2024